Greenland Mines Upsizes Offering to $38.4M at $12/Share with Pre-Funded Warrants
GRML has more than doubled off its 52-week low of $2.82 on elevated volume (8.1× avg).
Summary
Greenland Mines priced a $38.4 million direct offering at $12.00 per share—nearly double its August $20M raise—with pre-funded warrants for 1.4M additional shares, providing critical runway amid going concern and delisting pressures.
Key Events · Financing and Capital Events · GRML
-
Offering Upsized to $38.4M Net Proceeds
Direct registered offering of 1,765,420 common shares plus pre-funded warrants for 1,434,580 shares at $12.00 per share, expected to close September 24, 2026.
-
Nearly Double Prior Raise
Net proceeds of ~$38.4M compare to the $20M offering priced at $5.00/share on August 27, 2026—a materially larger capital injection at a higher per-share price.
-
Pre-Funded Warrant Structure
Warrants exercisable at $0.0001 per share with 4.99% (or 9.99% at election) beneficial ownership blockers; no expiration until fully exercised.
-
Private Warrant Exercise Price Amended
Company amended private warrants issued March 2, 2026 to a $5.00 post-reverse-split exercise price, aligning with the new capital structure.
Analysis · GRML · Life Sciences
A securities purchase agreement signed on September 23, 2026, sets up a direct registered offering expected to yield roughly $38.4 million in net proceeds—nearly double the $20 million raised just four weeks earlier at $5.00 per share. The new deal prices common stock and pre-funded warrants at $12.00 per share, reflecting the company's post-reverse-split share price and a significantly larger capital raise. The offering includes 1,765,420 common shares plus pre-funded warrants exercisable for up to 1,434,580 additional shares, with a 4.99% (or 9.99% at holder election) beneficial ownership blocker. The company also amended its private warrants to a $5.00 post-split exercise price. Proceeds are earmarked for Greenland mining operations, general corporate purposes, and working capital. This capital injection is critical given the going concern doubts and Nasdaq delisting deadline disclosed in the August 10-Q, but it comes with meaningful dilution to existing shareholders.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.6% of the 924 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRML was trading at $12.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.6M. The 52-week trading range was $2.82 to $36.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.